Theravance Announces Receipt of Additional FDA Communication Regarding Telavancin NDA for the Treatment of Nosocomial Pneumonia
Theravance Announces Receipt of Additional FDA Communication Regarding Telavancin NDA for the Treatment of Nosocomial Pneumonia
Jan 28, 2010